NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has announced additional details about its Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus (BDBV) outbreak and other Ebola viruses in the Democratic Republic of Congo. The trial is proceeding as designed, with enrollment in Phase IIA beginning on or about September 23, 2026. Phase IIA aims to identify an optimal, well-tolerated dosing regimen and will serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy. This update matters because it signals progress in developing an oral treatment for Ebola, a disease that has historically required complex intravenous therapies and has caused severe outbreaks in regions with limited healthcare infrastructure.
NV-387 is designed to attack the virus and reduce viral load, and it is delivered as an oral gummy that dissolves in the mouth without requiring water or swallowing effort. If successful, the oral treatment could be readily deployed in resource-limited settings, where conventional intravenous administration is challenging. NanoViricides characterizes NV-387 as a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses and says there is a rationale for potential activity against Bundibugyo and other Ebola viruses. This approach could simplify treatment logistics and improve patient access during outbreaks.
The company, which is creating special purpose nanomaterials for antiviral therapy, has a lead drug candidate in NV-387 that it plans to develop for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. Its other advanced candidate is NV-HHV-1 for Shingles. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. The company’s novel nanoviricide class of drug candidates is based on intellectual property and technology from TheraCour Pharma, Inc., with which it has a Memorandum of Understanding for the development of drugs for all antiviral infections.
For investors and industry observers, the progression of NV-387 into Phase II for Ebola underscores the potential of broad-spectrum antivirals to address multiple viral threats. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. The full press release can be viewed at https://ibn.fm/zjg8X. More information about the company is available at www.nanoviricides.com.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire and other services. The platform’s reach includes editorial syndication to 5,000+ outlets and social media distribution, ensuring that news like this reaches a wide audience of investors and industry professionals. For more details, visit BioMedWire.
